| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
D-Mannose-13C6 has no independent pharmacological target as a stable isotope tracer. The unlabeled D-mannose is a simple sugar that can be metabolized by the body and is involved in protein glycosylation. It has been used therapeutically for the prevention and treatment of urinary tract infections (UTIs) by preventing bacterial adhesion to uroepithelial cells. D-Mannose may also have immunomodulatory effects.
|
|---|---|
| ln Vitro |
Drug compounds have included stable heavy isotopes of carbon, hydrogen, and other elements, mostly as quantitative tracers while the drugs were being developed. Because deuteration may have an effect on a drug's pharmacokinetics and metabolic properties, it is a cause for concern [1].
As a stable isotope tracer, D-Mannose-13C6 is not tested for in vitro pharmacological activity. In cell culture studies, it is used to trace mannose metabolism, glycosylation pathways, and glucose-mannose interconversion. D-Mannose is incorporated into glycoproteins via the mannose-6-phosphate pathway. The 13C label enables precise tracking of carbon atoms through metabolic pathways. |
| ln Vivo |
D-Mannose-13C6 has no independent in vivo pharmacological activity as a therapeutic agent. It is used in animal studies as a stable isotope tracer to investigate carbohydrate metabolism, glycosylation pathways, and sugar transport mechanisms in various tissues. Unlabeled D-mannose has been studied for its potential therapeutic benefits in UTIs and in certain congenital disorders of glycosylation (CDGs).
|
| Enzyme Assay |
For in vitro LC-MS or NMR studies, D-Mannose-13C6 is dissolved in an appropriate solvent (water, PBS, or cell culture medium) to prepare a stock solution (e.g., 10-100 mM). For metabolic flux analysis, the tracer is added to cell culture media or enzyme reaction mixtures. Samples are collected at various time points, and metabolites are extracted. LC-MS or 13C-NMR is used to trace the 13C label into mannose-6-phosphate, fructose-6-phosphate, glycoproteins, and glycolytic intermediates.
|
| Cell Assay |
For in vitro cellular experiments, D-Mannose-13C6 can be added to cell culture media as a tracer. Cells (e.g., fibroblasts, cancer cells, kidney cells) are cultured in standard medium. The medium is replaced with glucose-free or reduced-glucose medium containing D-Mannose-13C6 (1-25 mM) for 1-48 hours. At each time point, cells are harvested, and metabolites are extracted. LC-MS is used to trace the 13C label into glycolytic intermediates, UDP-glucose, GDP-mannose, and glycosylated proteins. Glycosylation can be assessed by analyzing labeled glycopeptides.
|
| Animal Protocol |
For in vivo animal studies, D-Mannose-13C6 is administered to rodents via oral gavage or intravenous injection (e.g., 50-500 mg/kg). Blood samples are collected at multiple time points (0, 15, 30, 60, 120, 240 minutes). At terminal time points, tissues (liver, kidney, heart, brain, bladder) are harvested, snap-frozen, and stored at -80degC. Tissues are homogenized and analyzed by LC-MS or NMR to quantify 13C-labeled mannose and its metabolites. Urine can also be collected to assess mannose excretion.
|
| ADME/Pharmacokinetics |
D-Mannose-13C6 is a stable isotope tracer and has the same pharmacokinetics as natural D-mannose. D-Mannose is absorbed from the small intestine (Tmax ∼1-2 hours), distributed to tissues, and cleared primarily by the kidneys with a half-life of approximately 2-4 hours in humans. Unlike glucose, mannose is not significantly metabolized in most tissues; it is either directly excreted in urine or used for glycosylation. Oral mannose is well-tolerated and has high bioavailability.
|
| Toxicity/Toxicokinetics |
D-Mannose is a naturally occurring monosaccharide with very low toxicity. The LD50 in rodents is >10,000 mg/kg. Oral D-mannose is generally recognized as safe (GRAS) and is well-tolerated at doses up to 20 g/day in humans. Mild gastrointestinal side effects (diarrhea, bloating) may occur at very high doses. The 13C-labeled version is chemically identical and has the same safety profile. Standard laboratory safety precautions for handling carbohydrates apply.
|
| References | |
| Additional Infomation |
D-Mannose-13C6 is not a drug but a 13C-labeled stable isotope tracer. It has no approved therapeutic status as a labeled compound. It is used as a tracer for metabolic and biochemical studies to investigate carbohydrate metabolism, glycosylation pathways, and sugar transport mechanisms. It is commonly applied in cell culture experiments, in vivo metabolic flux analysis, and pharmaceutical research requiring accurate isotopic tracing. D-Mannose itself is used as a dietary supplement for UTI prevention. Available with ≥98 atom% 13C.
|
| Molecular Formula |
13C6H12O6
|
|---|---|
| Molecular Weight |
186.11
|
| Exact Mass |
186.083
|
| CAS # |
287100-74-7
|
| Related CAS # |
D-Mannose;3458-28-4
|
| PubChem CID |
71309140
|
| Appearance |
White to off-white solid powder
|
| Density |
1.6±0.1 g/cm3
|
| Index of Refraction |
1.573
|
| LogP |
-2.6
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
12
|
| Complexity |
151
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
O[C@H]([C@@H](CO)O)[C@@H]([C@@H](C=O)O)O
|
| InChi Key |
WQZGKKKJIJFFOK-APHFOIPNSA-N
|
| InChi Code |
InChI=1S/C6H12O6/c7-1-2-3(8)4(9)5(10)6(11)12-2/h2-11H,1H2/t2-,3-,4+,5+,6?/m1/s1/i1+1,2+1,3+1,4+1,5+1,6+1
|
| Chemical Name |
(3S,4S,5S,6R)-6-(hydroxy(113C)methyl)(2,3,4,5,6-13C5)oxane-2,3,4,5-tetrol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O: 250 mg/mL (1343.29 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.3732 mL | 26.8658 mL | 53.7317 mL | |
| 5 mM | 1.0746 mL | 5.3732 mL | 10.7463 mL | |
| 10 mM | 0.5373 mL | 2.6866 mL | 5.3732 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
